229 related articles for article (PubMed ID: 15797959)
1. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ
J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Grigg AP; Shuttleworth P; Reynolds J; Schwarer AP; Szer J; Bradstock K; Hui C; Herrmann R; Ebeling PR
J Clin Endocrinol Metab; 2006 Oct; 91(10):3835-43. PubMed ID: 16835281
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
5. Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy.
Ebeling PR
J Clin Endocrinol Metab; 2005 Jul; 90(7):4414-6. PubMed ID: 16002412
[No Abstract] [Full Text] [Related]
6. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
[TBL] [Abstract][Full Text] [Related]
10. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Nieminen M
Osteoporos Int; 1999; 10(2):128-36. PubMed ID: 10501793
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
13. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram SA; Peaston RT; Rawlings DJ; Francis RM; Thompson NP
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
[TBL] [Abstract][Full Text] [Related]
16. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
[TBL] [Abstract][Full Text] [Related]
17. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study.
Schulte C; Beelen DW; Schaefer UW; Mann K
Osteoporos Int; 2000; 11(4):344-53. PubMed ID: 10928225
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
20. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]